需生物制剂治疗的脊柱关节炎患者中的肺尖纤维囊泡性肺病
该研究扫描了2010至2021年间登记于HUR-BIO、有生物制剂改善病情抗风湿药(bDMARDs)适应证的3021例脊柱关节炎(SpA)患者记录,纳入其中2489例至少有一次胸部X线检查者。36例(1.4%)经X线和/或CT发现肺尖纤维囊泡性肺病(AFLD)。AFLD组男性比例更高、年龄更大、重度吸烟者更多、病程更长、QuantiFERON阳性率更高。作者结论指出AFLD的影像学表现可与结核混淆,对男性和长病程患者应特别注意鉴别结核。
要点
- 2489例有胸部X线检查的SpA患者中36例(1.4%)发现AFLD。
- AFLD组男性28例(77.8%)vs 非AFLD组1321例(53.9%),P=0.004。
- AFLD组年龄56.3(10.5)岁 vs 44.8(11.4)岁,P<0.001。
核心结论
- AFLD的影像学表现可与结核混淆,对男性和长病程患者应特别注意鉴别结核与AFLD。
研究设计与样本
- 回顾性扫描2010至2021年间登记于HUR-BIO、有bDMARDs适应证的3021例SpA患者记录,最终纳入2489例至少有一次胸部X线检查者。
- 记录内容包括人口学特征、合并症、实验室数据、使用的bDMARDs、基线DASs以及bDMARDs启动前的纯化蛋白衍生物和/或QuantiFERON检测结果。
主要发现
- 2489例中36例(1.4%)经X线和/或CT发现AFLD。
- AFLD组平均病程11.7(7.1)年。
- AFLD组男性28例(77.8%)vs 非AFLD组1321例(53.9%),P=0.004。
- AFLD组年龄56.3(10.5)岁 vs 非AFLD组44.8(11.4)岁,P<0.001。
关键数值与推荐
- AFLD组中阿达木单抗治疗较少被选用,而依那西普治疗更常被选用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The rate of pleuroparenchymal involvement in patients with SpA varies widely, from 0% to 85%. The most common form is apical fibrobullous disease (AFLD). The aim of this study was to determine the incidence of AFLD and associated factors in SpA patients under and/or planned to start biologic DMARDs (bDMARDs) therapy. METHODS: The records of 3021 SPA patients registered with HUR-BIO who had indication of bDMARDs between 2010 and 2021 were scanned. The study included 2489 patients with at least one chest radiograph (X-ray). Patient demographics, comorbidities, laboratory data, bDMARDs used, baseline DASs, and purified protein derivative and/or QuantiFERON test results before initiation of bDMARDs were recorded. RESULTS: Of the 2489 patients, 36 (1.4%) were found to have AFLD by X-ray and/or CT. The mean disease duration was 11.7 (7.1) years. Patients with AFLD were more likely to be male [28 (77.8%) vs 1321 (53.9%), P = 0.004], older [56.3 (10.5) years vs 44.8 (11.4) years, P < 0.001], heavy smokers [27 (79.4%) vs 1468 (60.9%), P = 0.028] and have had longer disease duration [17. 7 (9.7) years vs 11.6 (7) years, P = 0.001]. QuantiFERON positivity was higher in the AFLD group [9 (36%) vs 309 (16.1%), P = 0.013]. While treatment with adalimumab was less preferred in those with AFLD, treatment with etanercept was more frequently preferred. CONCLUSION: As the radiological findings of AFLD can be confused with those of tuberculosis, special attention should be paid to differentiating between tuberculosis and the disease in males and in patients who have had long disease duration.
引用
- Ozsoy Z, Ayan G, Durhan G, et al. Apical fibrobullous lung disease in spondyloarthritis patients with biologic DMARDs indication. Rheumatology (Oxford). 2024. PMID: 37498613. doi:10.1093/rheumatology/kead361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。